Assenagon Asset Management S.A. Agenus Inc Transaction History

Assenagon Asset Management S.A.

$47.8 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 17, 2024	BUY	$0.63 - $1.14 $1.41 Million - $2.54 Million	2,232,064 Added 3008.82%	2,306,248 $1.91 Million
Q3 2023 Nov 06, 2023	SELL	$1.12 - $1.88 $171,226 - $287,416	-152,881 Reduced 67.33%	74,184 $83,000
Q2 2023 Jul 25, 2023	BUY	$1.31 - $2.04 $70,957 - $110,498	54,166 Added 31.33%	227,065 $363,000
Q1 2023 Apr 18, 2023	BUY	$1.45 - $2.95 $250,703 - $510,052	172,899 New	172,899 $262,000
Q2 2022 Jul 27, 2022	SELL	$1.3 - $2.64 $205,306 - $416,929	-157,928 Reduced 49.05%	164,048 $318,000
Q1 2022 Apr 25, 2022	BUY	$2.35 - $3.47 $260,206 - $384,219	110,726 Added 52.41%	321,976 $792,000
Q4 2021 Feb 01, 2022	SELL	$2.92 - $5.74 $83,847 - $164,824	-28,715 Reduced 11.97%	211,250 $680,000
Q3 2021 Oct 19, 2021	SELL	$4.98 - $6.63 $3,565 - $4,747	-716 Reduced 0.3%	239,965 $1.26 Million
Q2 2021 Jul 15, 2021	BUY	$2.56 - $5.49 $392,742 - $842,248	153,415 Added 175.8%	240,681 $1.32 Million
Q4 2020 Feb 01, 2021	SELL	$3.17 - $4.49 $2.29 Million - $3.24 Million	-721,986 Reduced 89.22%	87,266 $277,000
Q3 2020 Oct 07, 2020	BUY	$2.98 - $5.2 $2.41 Million - $4.21 Million	809,252 New	809,252 $3.24 Million
Q2 2020 Jul 21, 2020	SELL	$2.29 - $4.24 $63,891 - $118,296	-27,900 Closed	0 $0
Q1 2020 Apr 17, 2020	BUY	$1.92 - $4.39 $53,568 - $122,480	27,900 New	27,900 $68,000
Q4 2019 Jan 17, 2020	SELL	$2.41 - $4.4 $93,310 - $170,359	-38,718 Closed	0 $0
Q3 2019 Oct 16, 2019	SELL	$2.17 - $3.14 $1.96 Million - $2.84 Million	-903,821 Reduced 95.89%	38,718 $100,000
Q2 2019 Aug 12, 2019	BUY	$2.53 - $3.04 $2.38 Million - $2.87 Million	942,539 New	942,539 $2.83 Million

Others Institutions Holding AGEN

# of Institutions

Shares Held

2.07M

Call Options Held

Put Options Held

View Full List

About AGENUS INC

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

More about AGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account